Increased mortality in elderly heart failure patients receiving infusion of furosemide compared to elderly heart failure patients receiving bolus injection

Rana Sager¹, Isak Lindstedt²,#, Lars Edvinsson¹,², Marie-Louise Edvinsson¹,²

¹Department of Emergency and Internal Medicine, Lund University Hospital of Skåne, Sweden
²Department of Medicine, Institute of Clinical Sciences in Lund, Lund University, Sweden

J Geriatr Cardiol 2020; 17: 359–364. doi:10.11909/j.issn.1671-5411.2020.06.009

Keywords: Furosemide; Heart failure; Infusion; Injection; Mortality

Heart failure (HF) is a condition of cardiac dysfunction and fluid overload. Neurohormonal activation via the renin-angiotensin-aldosterone system and the sympathetic nervous system are the pathophysiological cornerstones.¹ Furthermore, HF is a disorder widely associated with grave adverse outcomes and poor prognosis.² A loop diuretic is the fundamental drug used to prevent multiorgan failure and improve symptoms in these patients.³ Noteworthy worries have been put forth concerning the risks and benefits of loop diuretics, particularly about the dosage and administration procedure.⁴,⁵ Several observational studies have shown that static drug exposure is associated with increased mortality risk.⁶–¹⁵ Loop diuretics administered as a continuous infusion have been thought to convey further benefits over bolus injections.¹⁶ However, there is no consensus on whether loop diuretics administered intravenously as bolus injections or continuously as infusions are the better choice.¹⁷ Several meta-analyses have been performed to try to clarify the issue.¹⁷–²¹ They have shown support for administering furosemide as a continuous infusion rather than intermittent bolus injection for greater diuresis/urine volume¹⁷–¹⁹,²¹ and a greater reduction in total body weight.¹⁹–²¹ However, there was no benefit in terms of all-cause mortality.¹⁷,²¹ The aim of our study was to investigate the hypothesis that there would be a difference in outcome when elderly patients with severe HF are treated with loop diuretics administered as a continuous infusion compared to loop diuretics administered as bolus injections.

This was a single-center study of 40 Caucasian men and women who were hospitalized to the internal medicine ward at Skåne University Hospital in Lund because of worsened symptoms of their HF. All patients were enrolled into the study during the period January through September 2018, were in NYHA class III and IV, mean age over eighty, and had several concomitant diseases. The patients were randomly divided into two groups with 20 patients in each; one group that received intravenous loop diuretics as bolus and the other group receiving intravenous continuous loop diuretics as infusion. A thorough investigation of all the patient’s medical records during the time of hospitalization, re-hospitalizations within 30 days, and deaths within 90 days of discharge gave the relevant data to analyze. Exclusion criteria were malignancy-induced HF and chronic renal failure which required loop diuretics. The same loop diuretic was used for all patients (Furix 10 mg/mL, 4 mL ampulla; Takeda Pharma AB, Solna, Sweden). Bolus injections were given one or several times a day in total daily doses of between 20 to 100 mg furosemide. Continuous infusions were given typically between 4 to 10 hours a day at doses of 100 to 500 mg furosemide dissolved in 100 to 250 mL of Sodium Chloride 9% solution. Calculations for comparison between the two groups were done using the Student’s t-test for continuous variables and the Pearson’s chi-square test for dichotomous variables. Paired samples t-test was used when comparing in-group differences before and after intervention. Statistical significance was set at \( P < 0.05 \). Statistics were performed using the SPSS 25.0 statistical software (IBM SPSS Inc., Chicago, IL, USA).

The results are presented in Tables 1–3 and Figure 1. Overall, the baseline demographics were very similar between the two groups (Table 1) which demonstrated that the two groups were well matched. They were in their eighties, had the same female to male gender distribution, and had the same weight to length composition. Notably, they were also in the same NYHA class, 55% to 60% NYHA class IV. Basic blood tests, HF medication, and concomitant diseases did not differ significantly. However, patients in the group receiving furosemide as continuous infusions had signifi-
cantly lower systolic blood pressure ($P < 0.01$) at baseline. Since loop diuretic treatment has the ability to affect natriuretic peptides, weight, and renal function, these parameters were tested at both enrollment into the hospital and at discharge (Table 2). Generally, there were no significant differences in these parameters between the two groups. Furthermore, there was no significant change in variables from enrollment to discharge within the same group (Table 3). However, there was somewhat of a net reduction in N-terminal pro-brain natriuretic peptide (NT-proBNP) within both groups, but the reduction was not statistically significant.

The main finding of this study was that the mortality at three months after discharge from the hospital was significantly higher in the group of HF patients receiving furosemide as continuous infusions compared to the group receiving furosemide as intravenous bolus injections.

### Table 1. Basic demographic parameters.

| Variable               | Loop diuretic bolus injection | Loop diuretic continuous infusion | $P$-value |
|------------------------|-------------------------------|-----------------------------------|-----------|
| Age, yrs               | 20 84.6 ± 1.6                 | 20 80.1 ± 2.6                     | 0.15      |
| Gende, female          | 20 12 (60%)                   | 20 12 (60%)                       | N/A       |
| BMI, kg/m$^2$          | 15 26.7 ± 1.2                 | 15 25.1 ± 0.9                     | 0.31      |
| NYHA class IV          | 20 11 (55%)                   | 20 12 (60%)                       | 0.75      |
| SBP, mm Hg             | 20 140 ± 6.7                  | 20 116 ± 3.6                      | $< 0.01$  |
| DBP, mm Hg             | 20 81.7 ± 3.4                 | 20 73.0 ± 2.6                     | 0.06      |
| ECG QRS, ms            | 16 126 ± 7.7                  | 18 131 ± 8.4                      | 0.67      |
| Hemoglobin, g/L        | 19 125.9 ± 4.4                | 20 119.0 ± 4.6                    | 0.29      |
| Sodium, mmol/L         | 20 139.1 ± 1.0                | 20 137.1 ± 1.3                    | 0.26      |
| Potassium, mmol/L      | 20 4.4 ± 0.3                  | 20 4.2 ± 0.1                      | 0.61      |
| TNT, ng/L              | 18 122.2 ± 39.0               | 19 85.7 ± 29.6                    | 0.46      |
| Glucose, mmol/L        | 20 9.0 ± 0.8                  | 19 8.1 ± 0.6                      | 0.36      |
| CRP, mg/L              | 20 60.1 ± 21.5                | 20 18.1 ± 5.5                     | 0.07      |
| Total number           | 20 11.1 ± 0.9                 | 20 10.4 ± 1.0                     | 0.61      |
| ACE/ARB                | 20 12 (60%)                   | 20 8 (40%)                        | 0.21      |
| BB                     | 20 17 (85%)                   | 20 16 (80%)                       | 0.68      |
| MRA                    | 20 7 (35%)                    | 20 6 (30%)                        | 0.74      |
| Imdur                  | 20 6 (30%)                    | 20 3 (15%)                        | 0.26      |
| Warfarin               | 20 4 (20%)                    | 20 9 (45%)                        | 0.09      |
| NOAC                   | 20 9 (45%)                    | 20 4 (20%)                        | 0.09      |
| IHD                    | 20 13 (65%)                   | 20 9 (45%)                        | 0.20      |
| Hypertension           | 20 6 (30%)                    | 20 7 (35%)                        | 0.74      |
| Atrial fibrillation    | 20 9 (45%)                    | 20 10 (50%)                       | 0.75      |
| Stroke/TIA             | 20 6 (30%)                    | 20 4 (20%)                        | 0.47      |
| Diabetes               | 20 6 (30%)                    | 20 5 (25%)                        | 0.72      |
| Renal failure          | 20 4 (20%)                    | 20 5 (25%)                        | 0.71      |
| COPD/Asthma            | 20 7 (35%)                    | 20 2 (10%)                        | 0.06      |
| Re-admissions after 30 days | 17 4 (24%)                   | 15 6 (40%)                        | 0.32      |

Data are presented as means ± SE or $n$ (%). ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; BB: beta-blockers; BMI: body mass index; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; DBP: diastolic blood pressure; ECG: electrocardiogram; IHD: ischemic heart disease; MRA: mineralocorticoid receptor antagonist; N/A: not applicable; NOAC: novel oral anticoagulants; NYHA: New York Heart Association Classification; SBP: systolic blood pressure; TIA: transient ischemic attack; TNT: troponin T.
Table 2. Follow-up variables at enrollment and discharge.

| Variable                   | Loop diuretic bolus injection | Loop diuretic continuous infusion | P-value |
|----------------------------|-------------------------------|-----------------------------------|---------|
| NT-proBNP*, ng/L           | 20 9640 ± 22                  | 20 15901 ± 30                   | 0.10    |
| NT-proBNP#, ng/L           | 20 7380 ± 17                  | 20 12536 ± 24                   | 0.09    |
| Weight*, kg                | 20 73.7 ± 3.9                 | 20 71.7 ± 3.5                   | 0.71    |
| Weight#, kg                | 18 73.5 ± 4.2                 | 18 69.7 ± 3.3                   | 0.48    |
| Creatinine*, µmol/L        | 20 126.1 ± 12.2               | 20 141.1 ± 13.4                 | 0.42    |
| Creatinine#, µmol/L        | 20 126.2 ± 14.7               | 20 148.8 ± 17.1                 | 0.32    |
| eGFR*, mL/min per 1.73 m²  | 20 39.5 ± 3.0                 | 20 35.7 ± 3.3                   | 0.40    |
| eGFR#, mL/min per 1.73 m²  | 20 39.6 ± 2.9                 | 20 35.0 ± 3.7                   | 0.33    |

Data are presented as means ± SE. *Refer to enrollment. #Refer to discharge. eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro-brain natriuretic peptide.

Table 3. Change within variables from enrollment to discharge.

| Variable                   | Enrollment-discharge | P-value |
|----------------------------|----------------------|---------|
| NT-proBNP*, ng/L           | 20 2260 ± 17         | 0.21    |
| NT-proBNP#, ng/L           | 20 3366 ± 21         | 0.14    |
| Weight*, kg                | 20 1.14 ± 1.2        | 0.35    |
| Weight#, kg                | 18 1.43 ± 1.2        | 0.25    |
| Creatinine*, µmol/L        | 20 −0.10 ± 8.3       | 0.99    |
| Creatinine#, µmol/L        | 20 −7.75 ± 8.3       | 0.36    |
| eGFR*, mL/min per 1.73 m²  | 20 −0.10 ± 1.7       | 0.95    |
| eGFR#, mL/min per 1.73 m²  | 20 0.75 ± 1.9        | 0.70    |

Data are presented as means ± SE. *Refer to loop diuretic bolus injection. #Refer to loop diuretic continuous infusion. eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro-brain natriuretic peptide.

Figure 1. Mortality in heart failure patients (Bolus injection vs. Infusion of furosemide). Eight out of twenty patients in the infusion group were dead three months after discharge from the hospital, while two out of twenty patients in the bolus group were dead after three months. The difference between the two groups was significant, P = 0.03.

(Figure 1). Notably, at discharge (about one week later from enrollment), there was no significant difference in body weight in either treatment group, no change in the estimated glomerular filtration rate or in the serum creatinine levels. The treatment resulted in symptom relief and in a concomitant non-significant reduction in NT-proBNP (by 2260 ng/L in the bolus group and 3366 ng/L in the infusion group). Our results add important additional evidence to the current knowledge base for treating the elderly with severe HF.

The combined evidence up to date as depicted from the most recent meta-analyses published 2018 and 2019 have shown that there was no difference in mortality between the two modes of administering furosemide.[17,21] However, the interpretation of these meta-analyses is problematic. Overall, there were just too few deaths which makes any attempt of a certain conclusion leading the one way or the other impossible. Furthermore, the results from one meta-analysis[21] was weighted almost 75% on the study by Felker, et al.[22] which made the comparison a one-sided task. None the less, the trial by Felker, et al.[22] is important, since to the best of our knowledge, it is the largest of its kind. The trial showed that among patients with acute decompensated HF, there were no significant differences in patients’ assessment of symptoms or in the change in renal function when diuretic therapy was administered by bolus as compared with continuous infusion. Also, all-cause mortality was the same.[22]

Based on these findings, we must agree along with others that although providing important understandings into the
It has previously been shown that continuous infusions reduce NT-proBNP levels to a greater extent than bolus injections in both decompensated HF and in acute HF with renal dysfunction. On the contrary, we found presently that NT-proBNP in both groups of elderly severe HF patients were reduced to a similar extent by the two interventions. It is well known that increasing levels of NT-proBNP have been associated with increased mortality in HF patients and reductions in natriuretic peptides have in general been associated with improved outcomes. Considering this fact, we might have expected that meaningful decreases in NT-proBNP levels during the hospital stay would improve survival of the patients in the two groups. Yet, there were more deaths in the infusion group compared to the bolus group. The result could be interpreted in two main ways: (A) the infusion group could be somewhat frailer at baseline than the bolus group. In other words, the mode of administration of furosemide is merely a marker of disease severity. Even though infusion therapy decreased NT-proBNP levels to a similar extent as bolus therapy, the patients in the infusion group were worse off to start with inferring higher mortality risk regardless of treatment strategy. Without a doubt, persistent signs and symptoms of congestion at hospital discharge have been associated with high morbidity and mortality. Also, we have previously shown that elderly patients with severe HF that were admitted to the hospital with high blood pressure were better off than HF patients that presented with low blood pressure. Patients in the infusion group had significantly lower systolic blood pressure ($P < 0.01$) at baseline than the bolus group; and (B) alternatively, the infusion therapy, despite having favorable effects on NT-proBNP as did bolus therapy, conferred some additional detrimental effect because of the continuous administration procedure. Theoretically, however, the continuous infusion of furosemide seems superior to intermittent administration in some aspects. Steady delivery of the drug to the nephron leads to more effective diuresis by preventing diuretic resistance, i.e., rebound sodium retention and fluid reabsorption, and restricts potentially high-peak serum levels of furosemide that can increase toxicity when the drug is given as a bolus. Also, continuous infusion may decrease the fluctuations in intravascular volume. On the contrary, patients submitted to continuous infusion may be exposed to more persistent kidney damage, which promotes neuroendocrine overdrive, leading to increased tubulo-glomerular feedback. Also, continuous furosemide administration as an infusion often restricts the patient to his/her hospital bed increasing the likelihood of a worsened circulation, orthostatic hypotension, pulmonary edema, atelectasis, pneumonia and the like. Indeed, we have previously shown that orthostatic blood pressure is associated with increased mortality in elderly patients with HF. A thought would be that the way to administer furosemide might share aspects with those of nitric oxide drugs given as anti-anginal medication. Intermittent use preserves the efficacy while continuous administration reduces efficacy.

The concept of diuretic resistance can work both in favor of and disfavor of continuous and intermittent administration of loop diuretics. “The braking phenomenon”, a complex process that is due to changes in the structure and function of the kidney itself, triggering of the sympathetic nervous system, and alterations in several hormone pathways, could work in favor of intermittent administration. The efficacy of loop diuretics may weaken over time during long-term administration, as the body gradually adapts to their effects. “The post-diuretic effect”, which refers to increased sodium retention after the loop diuretic has metabolically worn off, can favor better efficacy with continuous administration. “The rebound effect”, which explains the occurrence of sodium retention when chronic loop diuretic use leads to compensated increased distal nephron sodium reabsorption, favors intermittent administration. Furosemide acts on the Na\(^+\)-K\(^-\)-2Cl\(^-\) cotransporter in the thick ascending limb of the loop of Henle to inhibit sodium and chloride reabsorption. The true pathophysiological pathways through which diuretics interact with the cardiovascular system and determine the prognosis of HF remain poorly investigated and understood. However, there are several potential harmful pathophysiological effects of furosemide that could cause adverse reactions in the human body. Hypokalemia or hypomagnesemia are frequently observed adverse drug reactions to furosemide. Potassium and magnesium abnormalities in patients with chronic HF could lead to potentially deleterious arrhythmogenic effects. Furosemide can cause intravascular volume depletion, leading to hypotension, reduced glomerular filtration rate, and renal dysfunction; renal dysfunction being a well-established predictor of mortality in hospitalized patients with HF.

Our study is unique in that it has examined very old patients, mean age over eighty. Almost all previous studies have included patients with a mean age between 50 and 70 years. This is important because it might be that the difference in mortality between bolus therapy and infusion therapy of loop diuretics only is apparent in the very elderly population. This fits well with the fact that the only other trial that also showed a clear significant increase in mortal-
ity (disfavoring continuous therapy) included patients with a mean age of around 80 years of age. The mortality rate is high in the very elderly population and it is possible that this is important in order to have the power to detect a difference. Accordingly, we suggest that more trials be performed in the very elderly to examine if the association between lower mortality with bolus therapy is true. Like many of the other trials studying the administration of furosemide as bolus and infusion, our trial was a small, single-center study. Thus, we also suggest that more trials be performed with at least the size of Felker, et al. However, management of elderly patients with severe HF is challenging and use of loop diuretics should be exercised with great care and only as symptomatic treatment.

Acknowledgments

This study was supported by the Swedish Heart-Lung Foundation and the Swedish SUS Funds. All authors had no conflicts of interest to disclose.

References

1 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2129–2200.
2 Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397–1402.
3 Zafar MR, Miller TW, Mustafa SF, et al. Pharmacological and non-pharmacological strategies for volume overload in acute decompensated congestive heart failure: a review article. Cureus 2020; 12: e6952.
4 Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147: 331–338.
5 McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004; 44: 1301–1307.
6 Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705–708.
7 Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using the propensity score methods. Eur Heart J 2006; 27: 1431–1439.
8 Ahmed A, Young JB, Love TE, et al. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol 2008; 125: 246–253.
9 Schartum-Hansen H, Loland KH, Svingen GF, et al. Use of loop diuretics is associated with increased mortality in patients with suspected coronary artery disease, but without systolic heart failure or renal impairment: an observational study using propensity score matching. PLoS One 2015; 10: e0124611.
10 Abdel-Qadir HM, Tu JV, Yun L, et al. Diuretic dose and long-term outcomes in the elderly patients with heart failure after hospitalization. Am Heart J 2010; 160: 264–271.e1.
11 Kapelos CJ, Kaldara E, Ntalianis A, et al. High furosemide dose has detrimental effects on survival of patients with stable heart failure. Hellenic J Cardiol 2015; 56: 154–159.
12 Harjari KJ, Dinshaw HK, Nunez E, et al. The prognostic implications of outpatient diuretic dose in heart failure. Int J Cardiol 1999; 71: 219–225.
13 Mielenzczuk LM, Tsang SW, Desai AS, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 2008; 14: 388–393.
14 Eshaghi S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97: 1759–1764.
15 Rodriguez-Ciller C, Menu D, d’Athis P, et al. Potentially inappropriate use of furosemide in a very elderly population: an observational study. Int J Clin Pract 2017; 71: 1–7.
16 Oh SW, Han SY. Loop diuretics in clinical practice. Electrolyte Blood Press 2015; 13: 17–21.
17 Ng KT, Velayit A, Khoo DKY, et al. Continuous infusion versus intermittent bolus injection of furosemide in critically ill patients: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2018; 32: 2303–2310.
18 Salvador DR, Ney RM, Ramos GC, et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005; 3: CD003178.
19 Amer M, Adomaityte J, Qayyum R. Continuous infusion versus intermittent bolus furosemide in ADHF: an updated meta-analysis of randomized control trials. J Hosp Med 2012; 7: 270–275.
20 Wu MY, Chang NC, Su CL, et al. Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials. J Crit Care 2014; 29: 2–9.
21 Kuriyama A, Urushidani S. Continuous versus intermittent administration of furosemide in acute decompensated heart failure: a systematic review and meta-analysis. Heart Fail Rev 2019; 24: 31–39.
22 Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797–805.
23 Hardin EA, Grodin JI. Diuretic strategies in acute decompensated heart failure. Curr Heart Fail Rep 2017; 14: 127–133.
24 Palazzuoli A, Pellegrini M, Ruocco G, et al. Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Crit Care 2014; 18: R134.
25 Palazzuoli A, Pellegrini M, Franci B, et al. Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. *Intern Emerg Med* 2015; 10: 41–49.

26 Andersson SE, Edvinsson ML, Björk J, et al. High NT-pro-BNP is a strong predictor of outcome in elderly heart failure patients. *Am J Geriatr Cardiol* 2008; 17: 13–20.

27 Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. Effect of B-type natriuretic peptide guided treatment of chronic heart failure on total mortality and hospitalisation: an individual patient meta-analysis. *Eur Heart J* 2014; 35: 1559–1567.

28 Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. *Eur Heart J* 2013; 34: 835–843.

29 Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Loop diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart failure: a report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD). *Circ J* 2012; 76: 1920–1927.

30 Lindstedt I, Edvinsson L, Edvinsson ML. Lower mortality in very elderly patients and heart failure patients admitted to the hospital having high blood pressure. *Cardiol Cardiovasc Med* 2019; 3: 204–220.

31 Lindstedt I, Edvinsson L, Lindberg AL, et al. Increased all-cause mortality, total cardiovascular disease and morbidity in hospitalized elderly patients with orthostatic hypotension. *Arch Gen Intern Med* 2018; 2: 8–15.

32 Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019; 21: 137–155.

33 Kim GH. Long-term adaptation of renal ion transporters to chronic diuretic treatment. *Am J Nephrol* 2004; 24: 595–605.

34 Wittner M, Di Stefano A, Wangemann P, et al. How do loop diuretics act? *Drugs* 1991; 41: 1–13.

35 Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. *Circulation* 1999; 100: 1311–1315.

36 Ng KT, Yap JLL. Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis of randomized controlled trials. *Anaesthesia* 2018; 73: 238–247.

37 Edvinsson ML, Stenberg A, Åström-Olsson K. Improved outcome with standardized plan for clinical management of acute decompensated chronic heart failure. *J Geriatr Cardiol* 2019; 16: 12–18.